Circulating biomarker results from a phase 2 study of seralutinib in pulmonary arterial hypertension
Year: 2026
Type: article
Abstract: Robin Osterhout, PhD, Athénaïs Boucly, MD, PhD, Raymond L Benza, MD, Richard N Channick, MD, Kelly M Chin, MD, Robert P Frantz, MD, Anna R Hemnes, MD, Luke
Authors: Robin Osterhout, Athénaïs Boucly, Raymond L Benza, Richard N Channick, Kelly M Chin, Robert P Frantz, Anna R Hemnes, Luke S Howard, Vallerie V McLaughlin, Olivier Sitbon, Jean-Luc Vachiéry, Roham T Zamanian, Richard Aranda, Matt Cravets, Zhaoqing Ding, Thao Duong-Verlé, David Mottola, Robert F Roscigno, Ravikumar Sitapara, Lawrence S Zisman, Jean-Marie Bruey, Hossein-Ardeschir Ghofrani
Institutions: Gossamer Bio (United States), Inserm, Université Paris-Saclay, Bicêtre Hospital, Imperial College London, Old Dominion University, Ronald Reagan UCLA Medical Center, UCLA Medical Center, The University of Texas Southwestern Medical Center, Mayo Clinic, Vanderbilt University Medical Center, Imperial College Healthcare NHS Trust, Hammersmith Hospital, University of Michigan, Université Libre de Bruxelles, Erasmus Hospital, Stanford Medicine, Stanford University, Justus-Liebig-Universität Gießen, German Center for Lung Research, Universities of Giessen and Marburg Lung Center, Cardio-Pulmonary Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funder: Gossamer Bio
OpenAlex ID: W7160707508